Mission Pharmacal Makes Deal With Meda AB To Become Elestrin Provider

San-Antonio based Mission Pharmacal has announced that it has entered into an agreement with Meda AB to become the exclusive U.S. provider of Elestrin. Elestrin is a topical hormone replacement gel used to treat women that are suffering from hot flashes as a result of menopause. Elestrin has already been approved by the FDA and currently is available as a prescription medicine in the US.

Mission has announced that it will be adding Elestrin to its growing line of branded women’s health products, which include bone-health products, anti-infectives, an iron supplement, a urinary analgesic, and prenatal vitamins. The company has traditionally focused on the women’s health sector.

Elestrin has had successful clinical trials, and the drug has been available since 2006 in the US. Hot flashes are considered one of the most common symptoms of menopause, which most women experience in their 40s and 50s. Elestrin is considered safe and effective for treating moderate to severe hot flashes.

Dan Kibbe, the senior vice president of Mission Pharmacal’s Pharmaceutical Division, released a statement on the new agreement. “Mission Pharmacal’s commitment to women’s health has never been stronger,” he said. “The addition of Elestrin further enhances our position as one of the most valuable partners in providing healthcare solutions for obstetricians and gynecologists and their patients in the women’s healthcare community.”

Brian Card, the Executive Director of Women’s Health and Urology Sales at Mission Pharmacal, echoed the sentiments relayed by Kibbe. Card went on to say that the partnership with Meda AB would bring value to physicians’ offices as the company’s women’s health offerings increased. “Our experienced women's health sales force is able to help general practitioners and OB/GYNs address a full range of everyday clinical situations,” he said.